Axim® Biotechnologies granted a “patent” for suppository formulations comprising of cannabinoids
AXIM® Biotechnologies, Inc., a world leader in cannabinoid research and product development, announced that the United States Patent and Trademark Office (USPTO) has issued the company a new Notice of Allowance for a patent (Application No. 16/122,079) on a suppository composition comprising cannabinoids.